Wan Ling TanKevin L.M. ChuaChia Chi LinVictor H.F. LeeLye Mun ThoAnthony W. ChanGwo Fuang HoThanyanan ReungwetwattanaJames C. YangDong Wan KimRoss A. SooYong Chan AhnHiroshi OnishiMyung Ju AhnTony S.K. MokDaniel S.W. TanFan YangPeking University People's HospitalNational Taiwan University HospitalNational Cancer Centre, SingaporeNational University Hospital, SingaporeSeoul National University HospitalSungKyunKwan University, School of MedicineFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityUniversity of Malaya Medical CentreUniversity of YamanashiThe University of Hong KongChinese University of Hong KongBeacon Hospital2020-03-262020-03-262020-03-01Journal of Thoracic Oncology. Vol.15, No.3 (2020), 324-34315561380155608642-s2.0-85080091130https://repository.li.mahidol.ac.th/handle/20.500.14594/53744© 2019 Stage III NSCLC represents a heterogeneous disease for which optimal treatment continues to pose a clinical challenge. Recent changes in the American Joint Commission on Cancer staging to the eighth edition has led to a shift in TNM stage grouping and redefined the subcategories (IIIA–C) in stage III NSCLC for better prognostication. Although concurrent chemoradiotherapy has remained standard-of-care for stage III NSCLC for almost 2 decades, contemporary considerations include the impact of different molecular subsets of NSCLC, and the roles of tyrosine kinase inhibitors post-definitive therapy and of immune checkpoint inhibitors following chemoradiotherapy. With rapid evolution of diagnostic algorithms and expanding treatment options, the need for interdisciplinary input involving multiple specialists (medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists and thoracic surgeons) has become increasingly important. The unique demographics of Asian NSCLC pose further challenges when applying clinical trial data into clinical practice. This includes differences in smoking rates, prevalence of oncogenic driver mutations, and access to health care resources including molecular testing, prompting the need for critical review of existing data and identification of current gaps. In this expert consensus statement by the Asian Thoracic Oncology Research Group, an interdisciplinary group of experts representing Hong Kong, Korea, Japan, Taiwan, Singapore, Thailand, Malaysia, and Mainland China was convened. Standard clinical practices for stage III NSCLC across different Asian countries were discussed from initial diagnosis and staging through to multi-modality approaches including surgery, chemotherapy, radiation, targeted therapies, and immunotherapy.Mahidol UniversityMedicineReviewSCOPUS10.1016/j.jtho.2019.10.022